scholarly journals Natural Products for the Management and Prevention of Breast Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-23 ◽  
Author(s):  
Sarmistha Mitra ◽  
Raju Dash
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Treatment Strategies ◽  
Chemical Compounds ◽  
Future Research ◽  
Breast Cancer Patients ◽  
Cancer Breast ◽  
Cancerous Cell ◽  
Long Time ◽  
Prevention Of Breast Cancer

Among all types of cancer, breast cancer is one of the most challenging diseases, which is responsible for a large number of cancer related deaths. Hormonal therapy, surgery, chemotherapy, and radiotherapy have been used as treatment of breast cancer, for a very long time. Due to severe side effects and multidrug resistance, these treatment approaches become increasingly ineffective. However, adoption of complementary treatment approach can be a big solution for this situation, as it is evident that compounds derived from natural source have a great deal of anticancer activity. Natural compounds can fight against aggressiveness of breast cancer, inhibit cancerous cell proliferation, and modulate cancer related pathways. A large number of research works are now focusing on the natural and dietary compounds and trying to find out new and more effective treatment strategies for the breast cancer patients. In this review, we discussed some significant natural chemical compounds with their mechanisms of actions, which can be very effective against the breast cancer and can be more potent by their proper modifications and further clinical research. Future research focusing on the natural anti-breast-cancer agents can open a new horizon in breast cancer treatment, which will play a great role in enhancing the survival rate of breast cancer patients.

scholarly journals Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B)

Breast Cancer ◽  
2021 ◽  
Author(s):  
Takamichi Yokoe ◽  
Sasagu Kurozumi ◽  
Kazuki Nozawa ◽  
Yukinori Ozaki ◽  
Tetsuyo Maeda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Real World ◽  
Treatment Strategies ◽  
Metastatic Breast ◽  
Trastuzumab Emtansine ◽  
Breast Cancer Patients ◽  
Her2 Positive

Abstract Background Trastuzumab emtansine (T-DM1) treatment for human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer after taxane with trastuzumab and pertuzumab is standard therapy. However, treatment strategies beyond T-DM1 are still in development with insufficient evidence of their effectiveness. Here, we aimed to evaluate real-world treatment choice and efficacy of treatments after T-DM1 for HER2-positive metastatic breast cancer. Methods In this multi-centre retrospective cohort study involving 17 hospitals, 325 female HER2-positive metastatic breast cancer patients whose post-T-DM1 treatment began between April 15, 2014 and December 31, 2018 were enrolled. The primary end point was the objective response rate (ORR) of post-T-DM1 treatments. Secondary end points included disease control rate (DCR), progression-free survival (PFS), time to treatment failure (TTF), and overall survival (OS). Results The median number of prior treatments of post-T-DM1 treatment was four. The types of post-T-DM1 treatments included (1) chemotherapy in combination with trastuzumab and pertuzumab (n = 102; 31.4%), (2) chemotherapy concomitant with trastuzumab (n = 78; 24.0%), (3), lapatinib with capecitabine (n = 63; 19.4%), and (4) others (n = 82; 25.2%). ORR was 22.8% [95% confidence interval (CI): 18.1–28.0], DCR = 66.6% (95% CI 60.8–72.0), median PFS = 6.1 months (95% CI 5.3–6.7), median TTF = 5.1 months (95% CI 4.4–5.6), and median OS = 23.7 months (95% CI 20.7–27.4). Conclusion The benefits of treatments after T-DM1 are limited. Further investigation of new treatment strategies beyond T-DM1 is awaited for HER2-positive metastatic breast cancer patients.

scholarly journals Self-perceived Risk of Breast Cancer and Screening Behaviors of First-degree Female Relatives of Breast Cancer Patients at the Uganda Cancer Institute, Uganda

2021 ◽  
Author(s):  
Provia Ainembabazi ◽  
Derrick Bary Abila ◽  
Grace Manyangwa ◽  
Godwin Anguzu ◽  
Innocent Mutyaba ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Early Detection ◽  
Cancer Patients ◽  
Breast Cancer Screening ◽  
Perceived Risk ◽  
Breast Cancer Patients ◽  
Perceived Risks ◽  
First Degree Relatives ◽  
Cancer Breast

Abstract Introduction In Uganda, Breast cancer is the most common cancer in females globally. The majority of the patients present with advanced-stage disease at diagnoses and experience high mortality. This underscores the importance of early detection approaches based on awareness of risk factors and self-perceived risks, and symptoms of the disease to promote adoption of risk reduction behaviors and prompt health-seeking respectively. This study assessed the self-perceived risk of breast cancer, and breast cancer screening behaviours among first-degree female relatives of breast cancer patients in Uganda.Methods This was a cross-sectional study employing quantitative approaches for data collection and analyses. First-degree female relatives of patients attending care at Uganda Cancer Institute were recruited consecutively in the study. A pre-tested coded questionnaire was used to collect data on self-perceived risks, breast cancer risks, and breast cancer screening behaviours. Data were collected between March to October 2019. A modified Poisson regression model was used to evaluate factors associated with self-perceived risk of breast cancer and breast cancer risk awareness.ResultsWe enrolled 296 first-degree female relatives from 197 female breast cancer patients. The median age (IQR) was 33 (26-43) years. A majority (60.1%, 178/296) of the participants had a low self-perceived risk of breast cancer. Breast self-examination (55.7%, 165/296) was the most practiced screening method followed by clinical breast examination (n= 64/296, 21.6%), ultrasound scan of the breast (7.8%, 23/296,), and mammogram (3.7%, 11/296). Women aged 35-44 years had a higher self-perceived risk of breast cancer (adjusted Incident Rate Ratio [aIRR]: 1.75, 95%CI: 1.10-2.80), compared to women aged 18-25 years. ConclusionFirst-degree relatives reported a low self-perceived risk of breast cancer. Breast cancer health education especially targeting younger women should emphasize the increased risk of breast cancer in first-degree relatives of patients with breast cancer. There is a need to increase awareness of breast cancer screening methods and their usefulness in the early detection of breast cancer among all women in Uganda.

scholarly journals Immunotherapy and prevention of breast cancer

2020 ◽  
Vol 7 (2) ◽  
pp. 58-70
Author(s):  
Neelam Thacker ◽  
Perianayagam Taneja
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Cancer Patients ◽  
Triple Negative ◽  
Standard Of Care ◽  
Breast Tumors ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Conventional Chemotherapy ◽  
Prevention Of Breast Cancer

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of cancer death in women worldwide. Despite the significant benefit of the use of conventional chemotherapy and monoclonal antibodies in the prognosis of breast cancer patients and although the recent approval of the anti-PD-L1 antibody atezolizumab in combination with chemotherapy has been a milestone for the treatment of patients with metastatic triple-negative breast cancer, immunologic treatment of breast tumors remains a great challenge. In this review, we summarize current breast cancer classification and standard of care, the main obstacles that hinder the success of immunotherapies in breast cancer patients, as well as different approaches that could be useful to enhance the response of breast tumors to immunotherapies.

scholarly journals Key Factors Contributing to Quality of Life for Breast Cancer Patients in Latvia: Supplementing Quantitative Surveys with Qualitative Interviews

2012 ◽  
Vol 12 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Agnese Dzērvīte ◽  
Maruta Pranka ◽  
Tana Lace ◽  
Ritma Rungule ◽  
Edvins Miklasevics ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Qualitative Interviews ◽  
Treatment Strategies ◽  
Well Being ◽  
University Hospital ◽  
Breast Cancer Patients ◽  
Key Factors

Summary Introduction. Health related quality of life is a much debated topic in medicine with much quantitative and qualitative research contributing to the understanding of how to improve the lives of patients, yet little has been published in relation to the quality of life of Latvian breast cancer patients. Aim of the Study. To gather base measurements of subjective and objective quality of life factors for breast cancer patients in Latvia and discover which key factors contribute most to quality of life of Latvian breast cancer patients at the start of treatment. Materials and Methods. This paper presents data collected from April 2010 to June 2011 at the Pauls Stradins Clinical University hospital on key factors influencing quality of life for breast cancer patients: health and physical well-being; state of surroundings and environment; social support and functionality; financial state, employment and leisure. Quantitative survey material has been supplemented with insight from qualitative in-depth interviews to better explain the objective and subjective implications for breast cancer patients’ quality of life. Results. Interviewed breast cancer patients rated their quality of life as being average or good at the beginning of treatment. Negative factors contributing to lowered quality of life were mainly linked to patient financial, social and emotional state at the first weeks of treatment and correspond to previous research done in Latvia on quality of life issues. Conclusions. Further follow-up surveys will contribute to the evaluation of breast cancer patients’ needs while undergoing treatment to further improve treatment strategies, especially if validated quality of life measurement surveys were to be implemented in Latvian hospitals.

Treatment strategies in elderly breast cancer patients: Is there a need for surgery?

The Breast ◽  
2014 ◽  
Vol 23 (6) ◽  
pp. 793-798 ◽  
Author(s):  
J.C. Sierink ◽  
S.M.M. de Castro ◽  
N.S. Russell ◽  
M.M. Geenen ◽  
E.Ph. Steller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Treatment Strategies ◽  
Breast Cancer Patients

Anticipatory Nausea and Vomiting Among Ovarian, Lymphoma, and Breast Cancer Patients Receiving Chemotherapy: Implications for Behavioural Treatment

1992 ◽  
Vol 9 (1) ◽  
pp. 25-31
Author(s):  
Peter W. Dunne ◽  
Matthew R. Sanders ◽  
John H. Kearsley
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Nausea And Vomiting ◽  
Future Research ◽  
Breast Cancer Patients ◽  
Anticipatory Nausea ◽  
Anticipatory Anxiety ◽  
Behavioural Treatment ◽  
Anticipatory Nausea And Vomiting

Cancer patients undergoing chemotherapy frequently experience anticipatory distress before treatment sessions. Eighty-six cancer patients (ovarian, lymphoma and breast) were assessed to determine the prevalence of anticipatory nausea and vomiting (ANV). Approximately one patient in three reported anticipatory nausea (AN), and of these 6 also experienced anticipatory vomiting (AV). Several patients reported anticipatory anxiety without any sensation of nausea. Clinically the notion of anticipatory distress may be more fruitful so that the problem of pretreatment anxiety is also addressed. Generally, AN was rated as moderate or worse in severity, occurred fairly consistently, and often began well before arrival at hospital on treatment day. It is suggested that future research should endeavour to link more closely the topography of the problem and the intervention techniques employed, as well as evaluating a broader range of possible interventions.

scholarly journals Genetic Mutations Associated with Hormone-Positive Breast Cancer in Ethiopian Women

2020 ◽  
Author(s):  
Alyssa D. Schwartz ◽  
Afua Adusei ◽  
Solomon Tsegaye ◽  
Christopher A. Moskaluk ◽  
Sallie S. Schneider ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African Americans ◽  
Cancer Patients ◽  
Tumor Tissue ◽  
Treatment Strategies ◽  
Breast Cancer Diagnosis ◽  
Breast Cancer Patients ◽  
European Descent ◽  
Matrix Encoding ◽  
New Treatment

AbstractIn Ethiopia, a breast cancer diagnosis is associated with a prognosis significantly worse than that of Europe and the US. Further, patients presenting with breast cancer in Ethiopia are far younger, on average, and patients are typically diagnosed at very late stages, relative to breast cancer patients of European descent. Emerging data suggest that a large proportion of Ethiopian patients have hormone-positive (ER +) breast cancer. This is surprising given 1) the aggressive nature of the disease, 2) that African Americans with breast cancer frequently have triple negative breast cancer (TNBC), and 3) these patients typically receive chemotherapy, not hormone-targeting drugs. To further examine the similarity of Ethiopian breast tumors to those of African Americans or of those of European descent, we sequenced matched normal and tumor tissue from Ethiopian patients from a small pilot collection. We identified mutations in 615 genes across all three patients, unique to the tumor tissue. Across this analysis, we found far more mutations shared between Ethiopian patient tissue and White patients (103) than we did comparing to African Americans (3). Several mutations were found in extracellular matrix encoding genes with known roles in tumor cell growth and metastasis. We suggest future mechanistic studies on this disease focus on these genes first, toward finding new treatment strategies for breast cancer patients in Ethiopia.

Sign in / Sign up

Export Citation Format

Share Document